EDAP Reports 25% Year-Over-Year Revenue Growth for Fourth Quarter 2012
2013年1月22日 - 10:00PM
Record full year revenue of approximately EUR 26.0 million (USD
33.5 million), up 16.5% year-over-year
Record fourth quarter total revenue of approximately EUR 9.4
million (USD 12.2 million), up 25% year-over-year
Record lithotripsy sales with 21 devices sold in fourth quarter
and 52 devices sold during full year
Cash position at December 31, 2012, of approximately EUR 8.0
million (USD 10.5 million), up EUR 1.5 million year-over-year
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today preliminary unaudited revenues for the
fourth quarter and full year ended December 31, 2012.
Preliminary total revenue for the fourth quarter 2012 is
expected to be approximately EUR 9.4 million (USD 12.2 million), a
25% year-over-year increase. Fourth quarter 2012 total revenue
reflected the sales of 21 lithotripters and three Ablatherm-HIFU
devices.
For the full year 2012, the Company reported record preliminary
total revenue of approximately EUR 26 million (USD 33.5 million),
up 16.5% compared to 2011. In aggregate, 52 lithotripsy
devices and four Ablatherm-HIFU devices were sold in 2012.
At December 31, 2012, the Company's cash position was
approximately EUR 8.0 million (USD 10.5 million). This EUR 1.5
million increase year-over-year was attributable to the Company's
financing activities and mostly to the capital raise and debt
reduction executed in early 2012. The Company's operations were
cash stable throughout the year.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We
are pleased with our robust sales growth for the fourth quarter and
full year. Our top line results were driven by the strong
sales trend across our lithotripsy business fueled by the continued
demand for our innovative Sonolith i-move lithotripter across new
and existing markets around the globe."
Mr. Oczachowski concluded, "During the fourth quarter, our sales
and marketing teams successfully converted our device backlog into
sales. This continues to validate the focused efforts of our teams
dedicated to expanding our market penetration in targeted markets,
including Europe and the U.S."
EDAP plans to hold a conference call to discuss its fourth
quarter and full year 2012 financial results on Tuesday April 2,
2013 at 8:30 am EDT.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm(R), the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multi-center U.S. Phase II/III clinical
trial under an Investigational Device Exemption (IDE) granted by
the FDA, the ENLIGHT U.S. clinical study. The Company also is
developing this technology for the potential treatment of certain
other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith(R) range) for treatment of urinary
tract stones using extra-corporeal shockwave lithotripsy (ESWL).
For more information on the Company, please visit
http://www.edap-tms.com, and http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among others
the uncertainties of the U.S. FDA approval process, the clinical
status and market acceptance of the Company's HIFU devices and
the continued market potential for the Company's lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
Ablatherm-HIFU treatment is in clinical trials, but not
FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 6 2024 まで 7 2024
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 7 2023 まで 7 2024